Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.

華控康泰集團有限公司
Kontafarma China Holdings Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1312)

POLL RESULTS OF THE ADJOURNED EXTRAORDINARY GENERAL MEETING HELD ON 7 NOVEMBER 2025

Reference is made to the notice of the extraordinary general meeting (the "**Notice**") of Kontafarma China Holdings Limited (the "**Company**") and the circular of the Company (the "**Circular**"), both dated 26 September 2025 and the announcement of the Company dated 16 October 2025 (the "**Announcement**") in relation to the adjournment of the EGM. Capitalised terms used herein have the same meanings as those defined in the Circular and the Announcement unless otherwise stated.

The Board hereby announces that at the Adjourned EGM held on 7 November 2025, the resolutions proposed (the "**Proposed Resolutions**") as set out in the Notice were duly passed by the Independent Shareholders by way of poll voting.

The poll results in respect of the Proposed Resolutions at the Adjourned EGM are set out as follows:

Ordinary Resolutions		No. of Shares Voted (percentage)	
		For	Against
a.	To approve, confirm and ratify in all respects the Beijing Construction Contract entered into between Tongfang Pharmaceutical (as principal), a direct wholly-owned subsidiary of the Company, and Beijing Qingkong (as contractor), pursuant to which Tongfang Pharmaceutical agreed to engage Beijing Qingkong as the general contractor to carry out the construction works for the Beijing R&D Complex Project at the contract price of RMB33,672,360.58 (subject to adjustments) and the transaction contemplated thereunder.	514,001,552 (100%)	0 (0%)
b.	To authorize any one of the Directors to do all such acts and things and execute and deliver all such documents, deeds or instruments (including affixing the common seal of the Company thereon) and take all such steps as the Director in his/her sole opinion and absolute discretion may consider necessary, appropriate or desirable to implement or give effect to the Beijing Construction Contract and the transaction contemplated thereunder.	514,001,552 (100%)	0 (0%)

As all of the votes were cast in favour of each of the above Proposed Resolutions, all of them were duly passed as ordinary resolutions by the Independent Shareholders at the Adjourned EGM.

As at the date of the Adjourned EGM, there were a total of 5,588,571,777 issued Shares. As disclosed in the Circular, China Health, being the controlling Shareholder, directly held 3,172,778,000 Shares, representing approximately 56.77% of the issued share capital of the Company as at the date of the Adjourned EGM. As China Health has a material interest in the Beijing Construction Contract and the transaction contemplated thereunder, accordingly, China Health was required to and had abstained from voting in relation to the Proposed Resolutions as set out in the Notice. Accordingly, the total number of Shares entitling the Independent Shareholders to attend and vote for or against the Proposed Resolutions at the Adjourned EGM was 2,415,793,777 Shares (representing approximately 43.23% of the total number of Shares in issue as at the date of the Adjourned EGM).

Save as disclosed above, (i) there were no Shares entitling the holders to attend and abstain from voting in favour of the Proposed Resolutions at the Adjourned EGM as set out in Rule 13.40 of the Listing Rules; (ii) no other Shareholder was required under the Listing Rules to abstain from voting on the Proposed Resolutions at the Adjourned EGM; and (iii) no Shareholders had stated their intention in the Circular to vote against or to abstain from voting on any of the Proposed Resolutions at the Adjourned EGM.

As at the date of the Adjourned EGM, there were no treasury Shares held by the Company (including any treasury Shares held or deposited with Central Clearing and Settlement System) and no voting rights of the treasury Shares have been exercised at the Adjourned EGM; and no repurchased Shares which are pending cancellation and should be excluded from the total number of issued Shares entitled to attend and vote on all the Proposed Resolutions at the Adjourned EGM.

The Directors, namely, Mr. Wang Feifei, Ms. Guo Zixiu, Mr. Liu Jiankun, Mr. Huang Yu, Dr. Tang Lai Wah, Dr. Ho Ho Ming and Mr. Yao Xiaomin, attended the Adjourned EGM except for Ms. Qiao Linna.

The Company's branch share registrar, Tricor Investor Services Limited, was appointed as the scrutineer for the vote-taking at the Adjourned EGM.

By order of the Board of
Kontafarma China Holdings Limited
Wang Feifei
Chairman

Hong Kong, 7 November 2025

As at the date of this announcement, the Board comprises four executive Directors, namely Mr. Wang Feifei (Chairman and President), Ms. Qiao Linna, Ms. Guo Zixiu (Financial Controller) and Mr. Liu Jiankun; one non-executive Director, namely Mr. Huang Yu; and three independent non-executive Directors, namely Dr. Tang Lai Wah, Dr. Ho Ho Ming and Mr. Yao Xiaomin.